Evolus Shares Rise on Jump in Revenue

Dow Jones

2025/01/21

By Don Nico Forbes

Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance.

Shares were up 16% in premarket trading at $12.20.

The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.

"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva," said Chief Executive David Moatazedi.

Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results.

The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days.

Write to Don Nico Forbes at don.forbes@wsj.com

(END) Dow Jones Newswires

January 21, 2025 09:12 ET (14:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2505276857"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505276857\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505276857?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505276857","market":"fut","top_or_hot":-1,"title":"Evolus Shares Rise on Jump in Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n</p>\n<p>\n  Shares were up 16% in premarket trading at $12.20. \n</p>\n<p>\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n</p>\n<p>\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n</p>\n<p>\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n</p>\n<p>\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 09:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus Shares Rise on Jump in Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus Shares Rise on Jump in Revenue\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-01-21 22:12</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n</p>\n<p>\n  Shares were up 16% in premarket trading at $12.20. \n</p>\n<p>\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n</p>\n<p>\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n</p>\n<p>\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n</p>\n<p>\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 09:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505276857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505276857","pubTimestamp":1737468720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance.Shares were up 16% in premarket trading at $12.20.The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.\"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi.Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results.The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form a","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc."},"translate_title":"Evolus股价因收入增长而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":0.9},"content_text":"By Don Nico Forbes \n\n\n \n\n\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n\n\n  Shares were up 16% in premarket trading at $12.20. \n\n\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n\n\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n\n\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n\n\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n\n\n \n\n\n  Write to Don Nico Forbes at don.forbes@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2025 09:12 ET (14:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}